BFS
ABUS icon

Bare Financial Services’s Arbutus Biopharma ABUS Stock Holding History

Bare Financial Services’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$869 Hold
181
– – ﹤0.01% 1429
2026
Q1 		$815 Hold
181
– – ﹤0.01% 1339
2025
Q4 		$871 Hold
181
– – ﹤0.01% 1184
2025
Q3 		$822 Buy
+181
New +$665 ﹤0.01% 1074

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bare Financial Services's ABUS Position: Q2 2026 in Review

Bare Financial Services held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 181 shares worth $869. The position accounts for ﹤0.01% of the portfolio, ranked #1429.

Bare Financial Services first reported a position in ABUS in Q3 2025 and has held it in 4 quarters since. The position peaked at $871 in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Bare Financial Services held 181 shares of Arbutus Biopharma worth $869 as of Q2 2026.
  • Bare Financial Services left its Arbutus Biopharma share count unchanged in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1429 holding.
  • Bare Financial Services first reported a position in Arbutus Biopharma in Q3 2025 and has held it in 4 quarters since.
  • Bare Financial Services's Arbutus Biopharma position peaked at $871 in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.